MR-Guided High-Power Microwave Ablation in Hepatic Malignancies: Initial Results in Clinical Routine.


Journal

Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 22 04 2020
accepted: 26 06 2020
pubmed: 24 7 2020
medline: 7 4 2021
entrez: 24 7 2020
Statut: ppublish

Résumé

Evaluation of technique effectiveness, patient safety and ablation parameters of MR-guided microwave ablation in hepatic malignancies using an MR-conditional high-power microwave ablation system. Institutional review board approval and informed patient consent were obtained. Patients who underwent MR-guided microwave ablation of hepatic malignancies in a 1.5T wide-bore scanner using a perfusion-cooled high-power microwave ablation system with a maximum generator power of 150 W were included. Ablation parameters comprising procedure durations, net ablation duration, applicator positions and ablation zone dimensions were recorded. Adverse events were classified according to the CIRSE classification system. Technique effectiveness was assessed after 1 month. Follow-up was conducted with contrast-enhanced MRI and ranged from 1 to 20 months (mean: 6.1 ± 5.4 months). Twenty-one consecutive patients (age: 63.4 ± 10.5 years; 5 female) underwent 22 procedures for 28 tumours (9 hepatocellular carcinomas, 19 metastases) with a mean tumour diameter of 14.6 ± 5.4 mm (range: 6-24 mm). Technique effectiveness was achieved in all lesions. Tumours were treated using 1.7 ± 0.7 applicator positions (range: 1-3). Mean energy and ablation duration per tumour were 75.3 ± 35.4 kJ and 13.3 ± 6.2 min, respectively. Coagulation zone short- and long-axis diameters were 29.1 ± 6.4 mm and 39.9 ± 7.4 mm, respectively. Average procedure duration was 146.4 ± 26.2 min (range: 98-187 min). One minor complication was reported. Five patients developed new tumour manifestations in the untreated liver. Local tumour progression was not observed during initial follow-up. MR-guided high-power microwave ablation provides safe and effective treatment of hepatic malignancies with short ablation times and within acceptable procedure durations.

Identifiants

pubmed: 32699978
doi: 10.1007/s00270-020-02584-5
pii: 10.1007/s00270-020-02584-5
pmc: PMC7591402
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1631-1638

Commentaires et corrections

Type : CommentIn

Références

Eur Radiol. 2019 Jul;29(7):3584-3594
pubmed: 30903328
Eur Radiol. 2017 Apr;27(4):1467-1476
pubmed: 27553935
Invest Radiol. 2008 Apr;43(4):211-8
pubmed: 18340244
J Magn Reson Imaging. 2018 Dec;48(6):1479-1488
pubmed: 30318672
Eur Radiol. 2012 Sep;22(9):1972-82
pubmed: 22527377
Invest Radiol. 2013 Jun;48(6):422-8
pubmed: 23399808
AJR Am J Roentgenol. 2010 Feb;194(2):523-9
pubmed: 20093619
Med Phys. 2014 Dec;41(12):123301
pubmed: 25471983
Eur Radiol Exp. 2019 Sep 23;3(1):39
pubmed: 31549338
Eur Radiol. 2015 Dec;25(12):3438-54
pubmed: 25994193
HPB (Oxford). 2018 Dec;20(12):1157-1162
pubmed: 29929785
Radiology. 2014 Oct;273(1):241-60
pubmed: 24927329
Med Ultrason. 2019 Aug 31;21(3):217-224
pubmed: 31476199
Cardiovasc Intervent Radiol. 2017 Dec;40(12):1962-1965
pubmed: 28593396
J Magn Reson Imaging. 2019 Feb;49(2):374-381
pubmed: 30221797
Eur Radiol. 2013 Jan;23(1):190-7
pubmed: 23085860
Eur Radiol. 2010 Aug;20(8):1985-93
pubmed: 20306080
J Magn Reson Imaging. 2018 Feb;47(2):316-331
pubmed: 28580706
Eur Radiol. 2019 Aug;29(8):4026-4035
pubmed: 30506218
Cardiovasc Intervent Radiol. 2018 Aug;41(8):1189-1204
pubmed: 29666906
Cardiovasc Intervent Radiol. 2017 Aug;40(8):1141-1146
pubmed: 28584945
Cardiovasc Intervent Radiol. 2014 Jun;37(3):777-83
pubmed: 24091751
J Vasc Interv Radiol. 2009 Sep;20(9):1224-9
pubmed: 19616970
AJR Am J Roentgenol. 2012 Jan;198(1):W46-50
pubmed: 22194514
Oncol Lett. 2018 Mar;15(3):2913-2920
pubmed: 29435018
Eur Radiol. 2013 Jun;23(6):1487-94
pubmed: 23314597
Int J Hyperthermia. 2017 Feb;33(1):15-24
pubmed: 27416729
Cardiovasc Intervent Radiol. 2014 Jun;37(3):723-9
pubmed: 24196263

Auteurs

Moritz T Winkelmann (MT)

Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany.

Georg Gohla (G)

Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany.

Jens Kübler (J)

Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany.

Jakob Weiß (J)

Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany.

Stephan Clasen (S)

Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany.

Konstantin Nikolaou (K)

Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany.

Rüdiger Hoffmann (R)

Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany. Ruediger.Hoffmann@med.uni-tuebingen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH